This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Transplantation				
Graft-versus-host disease (GvHD)	ATP synthase H ⁺ transporting mitochondrial F1 complex O subunit (ATP5O; OSCP)	Studies in mice suggest that inhibiting ATP5O could help treat GvHD. In a mouse model of GvHD, injection of Bz-423, a small molecule inhibitor of ATP5O, induced superoxide production and apoptosis in alloreactive T cells and prolonged survival compared with injection of vehicle control. Next steps include studying the effect of Bz-423 on GvHD and identifying the signaling pathways that cause altered metabolic phenotypes in alloreactive T cells. Lycera Corp. has compounds derived from Bz-423 in preclinical development to treat autoimmune diseases.	Patent application filed; exclusively licensed to Lycera	Gatza, E. <i>et al. Sci. Transl. Med.</i> ; published online Jan. 26, 2011; doi:10.1126/scitranslmed.3001975 Contact: James L.M. Ferrara, University of Michigan, Ann Arbor, Mich. e-mail: ferrara@med.umich.edu
<i>SciBX</i> 4(8); doi:10.1038/scibx.2011.231 Published online Feb. 24, 2011				